Andrea Carlini

Dr. Andrea Carlini

University of Bologna, Bologna, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
DFDaria Maria Filippini
Daria Maria Filippini
Donatella RomanielloDonatella Romaniello
Donatella Romaniello
FCFrancesca Carosi
Francesca Carosi
LFLaura Fabbri
Laura Fabbri
ACAndrea Carlini
Andrea Carlini
LLLaura Locati
Laura Locati
Background: Growth Differentiation Factor 15 (GDF15) has emerged as a key biomarker and therapeutic target in oncology, with roles extending beyond cancer cachexia. Elevated GDF15 levels correlate with poor prognosis across several solid tumors, including colorectal, gastric, pancreatic, breast, lung, prostate, and head and neck cancers. GDF15 modulates tumor progression through PI3K/AKT, MAPK/ERK, and SMAD2/3 signaling, thereby promoting epithelial-to-mesenchymal transition, metastasis, immune evasion, and chemoresistance via Nrf2 stabilization and oxidative stress regulation. Methods: We performed a narrative review of the literature focusing on the role of GDF15 in solid tumors, with a particular emphasis on head and neck cancers. Results: In head and neck squamous cell carcinoma (HNSCC), GDF15 overexpression is linked to aggressive phenotypes, radioresistance, poor response to induction chemotherapy, and failure of immune checkpoint inhibitors (ICIs). Similar associations are observed in colorectal, pancreatic, and prostate cancer, where GDF15 contributes to metastasis and therapy resistance. Targeting the GDF15-GFRAL axis appears therapeutically promising: the monoclonal antibody ponsegromab improved cachexia-related outcomes in the PROACC-1 trial, while visugromab combined with nivolumab enhanced immune response in ICI-refractory tumors. Conclusions: Further investigation is warranted to delineate the role of GDF15 across malignancies, refine patient selection, and evaluate combinatorial approaches with existing treatments.

23 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SSSara Stumpo
Sara Stumpo
ACAndrea Carlini
Andrea Carlini
FMFrancesco Mantuano
Francesco Mantuano
Alessandro Di FedericoAlessandro Di Federico
Alessandro Di Federico
BMBarbara Melotti
Barbara Melotti
Andrea De GiglioAndrea De Giglio
Andrea De Giglio
Background: Docetaxel is the standard of care for advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy and/or immunotherapy but is associated with modest clinical outcomes and considerable toxicity. Sacituzumab govitecan and datopotamab deruxtecan are trophoblast cell surface antigen (TROP)-2-directed antibody–drug conjugates (ADCs) that showed encouraging activity in pretreated patients with advanced NSCLC. This systematic review and pooled analysis aims to comprehensively assess the efficacy and safety of anti-TROP-2 ADCs compared to docetaxel in pretreated patients with advanced NSCLC. Methods: A systematic search through PubMed and EMBASE before 31 January 2025 was performed to identify eligible studies. Randomized controlled phase III trials comparing an anti-TROP-2 regimen to docetaxel in patients with pretreated advanced NSCLC were included. Overall survival (OS), progression-free survival (PFS), and grade ≥ 3 treatment-related adverse events (TRAEs) were extracted from the identified trials. A pooled analysis of reconstructed patient data and meta-analysis employing the random-effect model were used to summarize the efficacy and safety outcomes. Results: Across the two trials included, 1207 patients were enrolled, 598 in the TROP-2 ADC arm and 609 in the docetaxel arm. Anti-TROP-2 treatment did not produce significant improvements in OS (HR: 0.90; 95% CI, 0.78–1.03; P = 0.13) and PFS (HR: 0.84; 95% CI, 0.68–1.02; P = 0.08), compared to docetaxel, even in patients with a nonsquamous histology (OS HR: 0.86; 95% CI, 0.73–1.01; P = 0.06; PFS HR: 0.76; 95% CI, 0.52–1.12; P = 0.17). Across the subgroup analyses, a statistically significant improvement in OS was observed in patients with actionable genomic alterations (AGAs) (HR: 0.63; 95% CI, 0.41–0.95; P = 0.03). Compared to docetaxel, the anti-TROP-2 regimen demonstrated a lower risk of developing grade ≥ 3 TRAEs (RR: 0.76; 95% CI, 0.55–1.05; P = 0.09). Conclusions: The anti-TROP-2 regimen showed a better safety profile but failed to demonstrate a relevant clinical improvement over docetaxel. Anti-TROP-2 ADCs could find a role in the management of patients with AGAs.

5 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ACAndrea Carlini
Andrea Carlini
ESEmanuela Scarpi
Emanuela Scarpi
CBCarla Bettini
Carla Bettini
AAAndrea Ardizzoni
Andrea Ardizzoni
CDCostanza Maria Donati
Costanza Maria Donati
RRRomina Rossi
Romina Rossi
Cachectic patients frequently require transdermal fentanyl (TDF) for pain management, but data on its efficacy and safety are scarce and inconsistent. This scoping review aims to analyze the evidence concerning TDF administration in patients with cachexia irrespective of the underlying pathology. The primary objective is to assess the analgesic efficacy and tolerability of TDF in cachectic patients. The secondary objective is to identify cachexia characteristics that may influence fentanyl pharmacokinetics (PK). A comprehensive search of PubMed, Embase, and Web of Science databases was conducted up to March 2024. The review included observational and clinical studies on cachectic patients with moderate to severe pain treated with TDF patches at any dosage or frequency. Phase 1 trials, animal studies, case reports, preclinical studies and conference abstracts were excluded. Nine studies were included: four studies reported that cachexia negatively impacted TDF efficacy, increasing required doses and lowering plasma concentrations; three studies found minimal or no impact of cachexia on TDF efficacy and PK; two studies suggested that cachexia might improve TDF outcomes. Study quality ranged from moderate to high, according to the National Institutes of Health (NIH) Quality Assessment Tool. The current evidence is insufficient to provide any definitive recommendations for TDF prescribing in cachectic patients.

17 August 2026 in Frontiers in Pain Research
Verified
Journal Article
Open access
PDF file
LALucia Angelini
Lucia Angelini
IAIrene Azzali
Irene Azzali
ACAndrea Carlini
Andrea Carlini
VAVincenza Andrisano
Vincenza Andrisano
SMSerena Montanari
Serena Montanari
MRMarianna Ricci
Marianna Ricci
Background/objectives: Transdermal fentanyl (TDF) is widely used for moderate-to-severe cancer pain, yet substantial variability in fentanyl exposure, analgesic response, and tolerability remains incompletely explained by clinical factors. We evaluated whether pharmacogenetic variability is associated with pharmacokinetic parameters and clinical outcomes in cancer patients receiving TDF. Methods: In this prospective, single-center study, adults with solid or hematological malignancies and chronic cancer pain treated with stable-dose 72 h TDF were enrolled. Blood samples were collected for pharmacokinetic and pharmacogenetic analyses. Serum fentanyl concentrations were quantified using validated gas chromatography–mass spectrometry, and AUC, C max , and t max were calculated using non-compartmental analysis. Genotyping was performed using a predefined pharmacogenetic panel. Analgesic response was defined as a ≥2-point reduction in Numeric Rating Scale score or score = 0 at 72 h. Statistical analyses included correction for multiple testing. Results: 49 patients were included (median age 65 years; 98% stage IV disease); 38 (77.5%) were responders. No significant differences in AUC, C max , or t max were observed between responders and non-responders. TPMT and UGT2B7 variants showed unadjusted associations with clinical response and pharmacokinetic parameters, respectively; however, none remained statistically significant after correction for multiple testing. No significant associations were observed for CYP3A4/5 or ABCB1 variants, nor between genetic variants and adverse events. Pain reduction correlated with improved functional outcomes. Conclusions: In this exploratory cohort, pharmacogenetic variability was not robustly associated with TDF pharmacokinetics, analgesic response, or tolerability after correction for multiple testing. These findings do not support the current clinical implementation of pharmacogenetic-guided TDF therapy, but provide hypothesis-generating signals for future studies.

5 August 2026 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
ESEmanuela Scarpi
Emanuela Scarpi
VVVanessa Valenti
Vanessa Valenti
MDMonia Dall'Agata
Monia Dall'Agata
IBIlaria Bassi
Ilaria Bassi
LALucia Angelini
Lucia Angelini
RRRomina Rossi
Romina Rossi
Background: The increasing prevalence of chronic diseases makes identifying patients in need of palliative care essential for public health systems. Several tools have been developed to identify patients with palliative care needs and limited life expectancy. This study aimed to evaluate the performance of the NECPAL and PaP tools in patients with advanced chronic diseases and to explore their potential role in identifying palliative care needs and prognostic assessment. Methods: Prospective, observational, multicenter study using the Necesidades Paliativas tool (NECPAL CCOMS-ICO version 1.0), Palliative Prognostic score (PaP score), and functional and symptom assessment tools (Palliative Performance Scale and Edmonton Symptom Assessment System), assessed monthly or every two months for up to 12 months. Information on healthcare utilization and end-of-life care was also collected. Sensitivity, specificity, positive/negative predictive value and accuracy were calculated. The study included three groups of patients with advanced chronic diseases: cancer, pulmonary diseases, and renal diseases. The study was reported following the STROBE guidelines. Results: One hundred and ninety-three patients were enrolled: 102 with advanced cancer, 50 with chronic respiratory failure, and 41 with chronic renal failure. The median age was 75 years and 63.7% were male. The overall survival rate was 90% at 30 days and 65% at 12 months. At 30 days, sensitivity and specificity were 100% and 88% for the PaP score, and 89% and 39% for NECPAL. At 12 months, sensitivity and specificity were 20% and 89% for the PaP score, and 88% and 41% for NECPAL. Prognostic accuracy was higher for the PaP score at 30 days (91%) and higher for the NECPAL tool at 12 months (81%). Patients with cancer had more frequent hospitalizations in acute units, while the people living with pulmonary disease had more total hospitalization days. Conclusions: The findings suggest that the two instruments may provide complementary information, although the potential benefit of a combined strategy was not directly evaluated in this study.

7 August 2026 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
ACAndrea Carlini
Andrea Carlini
MBMirea Berti
Mirea Berti
GLGiuseppe Lamberti
Giuseppe Lamberti
EAElisa Andrini
Elisa Andrini
FCFrancesca Carosi
Francesca Carosi
DCDavide Campana
Davide Campana
Objectives: Head and neck paragangliomas (HNPGLs) are rare neuroendocrine tumors with heterogeneous behavior, making prognostic assessment challenging. Although generally indolent, a subset exhibits malignant potential, and robust prognostic determinants remain insufficiently defined. This study aimed to identify clinical and pathological factors independently associated with overall survival (OS) in patients with HNPGLs. Methods: We performed a retrospective Surveillance, Epidemiology, and End Results (SEER)-based cohort study (1975-2021). Demographic, clinicopathologic, and treatment variables were evaluated using Kaplan–Meier survival estimates, Cox regression models, and receiver operating characteristic (ROC)-derived cutoffs. Results: Among 280 patients, most tumors originated in the carotid body (77.5%). In univariable analyses, extra-carotid location, tumor size ≥ 34.5 mm, absence of surgery, advanced stage, and older age were associated with poorer OS. In multivariable analysis, older age, advanced stage, and lack of surgery remained independently associated with reduced OS. Conclusions: Age at diagnosis, disease stage, and surgical resection status were independently associated with OS, with stage emerging as the strongest determinant in HNPGLs. Associations involving tumor size and extra-carotid location should be interpreted as exploratory findings.